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Abstract
Background: Currently available therapies for Alzheimer’s disease (AD) do not treat the underlying cause of AD.
Anecdotal observations in nursing homes from multiple studies strongly suggest an inverse relationship between
cancer and AD. Therefore, we reasoned that oncology drugs may be effective against AD.
Methods: We screened a library of all the FDA-approved oncology drugs and identified bis-chloroethylnitrosourea
(BCNU or carmustine) as an effective amyloid beta (Ab) reducing compound. To quantify Ab levels, Chinese
hamster ovary (CHO) cells stably expressing amyloid precursor protein 751WT (APP751WT) called 7WD10 cells were
exposed to different concentrations of BCNU for 48 hours and the conditioned media were collected. To detect Ab
the conditioned media were immunoprecipitated with Ab9 antibody and subjected to immunoblot detection.
Amyloid plaques were quantified in the brains of a mouse model of AD after chronic exposure to BCNU by
thoflavin S staining.
Results: BCNU decreased normalized levels of Ab starting from 5 μM by 39% (P < 0.05), 10 μM by 51% (P < 0.01)
and 20 μM by 63% (P < 0.01) in CHO cells compared to a control group treated with butyl amine, a structural
derivative of BCNU. Interestingly, soluble amyloid precursor protein a (sAPPa) levels were increased to 167% (P <
0.01) at 0.5 μM, 186% (P < 0.05) at 1 μM, 204% (P < 0.01) at 5 μM and 152% (P < 0.05) at 10 μM compared to
untreated cells. We also tested the effects of 12 structural derivatives of BCNU on Ab levels, but none of them
were as potent as BCNU. BCNU treatment at 5 μM led to an accumulation of immature APP at the cell surface
resulting in an increased ratio of surface to total APP by 184% for immature APP, but no change in mature APP. It
is also remarkable that BCNU reduced Ab generation independent of secretases which were not altered up to 40
μM. Interestingly, levels of transforming growth factor beta (TGFb) were increased at 5 μM (43%, P < 0.05), 10 μM
(73%, P < 0.01) and 20 μM (92%, P < 0.001). Most significantly, cell culture results were confirmed in vivo after
chronic administration of BCNU at 0.5 mg/kg which led to the reduction of Ab40 by 75% and amyloid plaque
burden by 81%. Conversely, the levels of sAPPa were increased by 45%.
Conclusions: BCNU reduces Ab generation and plaque burden at non-toxic concentrations possibly through
altered intracellular trafficking and processing of APP. Taken together these data provided unequivocal evidence
that BCNU is a potent secretase-sparing anti-Ab drug.
See related commentary article here http://www.biomedcentral.com/1741-7015/11/82
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Background
Alzheimer’s disease (AD) is a devastating neurodegenera-
tive disorder of older persons presented with progressive
intellectual deterioration involving memory, language,
judgment and problem solving ultimately leading to a
total dependence on nursing care. Recent statistics sug-
gest that nearly 35.6 million patients are affected by AD
worldwide and that about 4.6 million new cases are
added each year causing an enormous social and eco-
nomic burden [1]. While death rates due to stroke, heart
disease and cancer have a decreasing trend, deaths
related to AD have actually increased by 66% between
2000 and 2008 [2]. AD is responsible for causing more
than 100,000 deaths each year with a total annual cost of
care and treatment exceeding $100 billion in the United
States alone [2,3]. Accumulation of amyloid plaques com-
posed of amyloid b peptide (Ab), derived from amyloid
precursor protein (APP) by consecutive actions of b- and
g-secretases is a major hallmark of AD. Although the
causal relationship between Ab and AD is not firmly
established, increasing genetic, biochemical and patholo-
gical evidence strongly implies that Ab has an early and
crucial role in AD pathogenesis [4]. Therefore, most
research efforts are now focused on reducing the levels of
Ab. More specifically, the biogenesis of Ab has been the
prime validated drug target for AD. With the failure of
anti-amyloid therapy to improve cognitive measures in
clinical trials including the most recent (semagacestat
[5,6], homotaurine [7] tarenfurbil [8] and bapineuzumab
[9]), the so called amyloid ‘naysayers’ are vocally suggest-
ing that anti-amyloid therapeutic approaches be aban-
doned. However, improved cognitive measures that
correlate well with decreased Ab levels, even up to 4.5
years after the initial vaccination with Ab in clinical trials
[10,11], strongly support Ab’s causal role in AD and
clearly suggest that reducing Ab levels in the brains of
AD patients is an effective approach for successful ther-
apy. Moreover, accelerated cortical atrophy continues to
be well correlated with high Ab deposition in multiple
studies which used the most advanced technology and
tracing compounds, further strengthening the pivotal
role of Ab in AD [12,13].
At present, the number of therapeutic options for AD
remains severely limited. Currently, there are five US Food
and Drug Administration (FDA)-approved drugs available
for the treatment of AD which target either increasing
cholinergic transmission or reducing glutamatergic trans-
mission. None of them can stop or even slow down the
underlying neurodegenerative process because there is an
extensive multifocal neurodegeneration occurring due to
accumulation of Ab. These drugs do not alter this under-
lying cause. So far, nearly 1,000 clinical trials have been
attempted throughout the world to validate an effective
therapy for AD based on all possible mechanisms of action
including, in the most recent years, both b- and g-secretase
inhibitors [14]. The classes of drugs being investigated
include growth factors, Ca2+ antagonists, intravenous
immunoglobulin, alpha secretase stimulators, Ab oligomer
inhibitors, metal chelators, neuroprotective agents, choles-
terol lowering drugs, anti-inflammatory agents, anti-epi-
leptics and immunization [15]. Unfortunately, instead of
improving their cognitive measures, many patients experi-
enced worsening of the symptoms and some patients even
developed skin cancer after treatment with semagacestat, a
g-secretase inhibitor [5,6]. The most likely explanation for
the failure of g-secretase inhibitors in the clinical trials is
because g-secretase has dozens of target proteins particu-
larly notch signaling which is crucial for cell-cell commu-
nication, immune system formation and cell proliferation
and survival [16]. For b-secretase (BACE), in addition to
having dozens of other substrates, the active site is so
large that only compounds with more than 500 molecular
weight may efficiently inhibit the enzyme, but then they
are unable to pass through the blood-brain barrier (BBB)
[17]. More importantly, multiple labs have reported that
BACE1 deficiency in genetically engineered mice is asso-
ciated with impaired learning [18], further defeating the
very purpose for which it is intended. Although effective
BACE inhibitors have been shown in recent years to lower
Ab levels in animal models [19,20], overall, secretase inhi-
bitors have so far failed to demonstrate the expected effi-
cacy against AD [6]. Therefore, alternative targets that
may modulate Ab generation, preferably without directly
inhibiting g-secretase or BACE, are very important at this
juncture.
Significantly, Ab has been implicated to play a vital role
in the pathogenesis of not only AD but also traumatic
brain injury (TBI) [21], cerebral amyloid angiopathy
(CAA) [22], glaucoma [23] and Niemann-Pick type C dis-
ease [24]. As with AD, there are no effective prevention or
treatment strategies for these disorders. Therefore, devel-
opment of any safe secretase-sparing anti-Ab drug would
have wider clinical applications.
It is also important to note that there is a strong rela-
tionship between cancer and AD. For instance, a recent
population based cohort study revealed a 43% lower risk
of ever developing AD among cancer patients [25]. Simi-
larly, patients diagnosed with AD showed a 69% lower risk
of developing cancer [25]. These observations have been
confirmed by longitudinal prospective studies [26].
Because of the solid relationship between AD and cancer,
we speculated that anticancer drugs may exert favorable
effects on AD. Therefore, we decided to screen all FDA-
approved oncology drugs in a cell-based assay and identi-
fied bis-chloroethylnitrosourea (BCNU or carmustine) as a
potential anti-Ab drug.
Here we show for the first time that BCNU-exposed
Chinese hamster ovary (CHO) cells have significantly
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reduced levels of amyloid b peptide (Ab) and c-terminal
fragments (CTFs) in cell cultures. Also, chronic adminis-
tration of BCNU for 60 days in a mouse model of AD
robustly decreased levels of Ab40 and amyloid plaque
burden at six months of age. More importantly, Ab
levels and plaque burden were reduced at non-toxic
concentrations of BCNU independent of secretases sug-
gesting that BCNU may be an effective Ab lowering, dis-
ease-modifying drug against AD.
Methods
Chemicals and antibodies
The FDA-approved oncology drug set II was obtained
from the open chemical repository of the National Cancer
Institute/National Institutes of Health Developmental
Therapeutics Program (NCI/NIH DTP) [27]. 1, 3 bis (2-
chloroethyl)-1-nitrosourea (BCNU) or carmustine (cat#
C0400), thioflavin S (cat #T1892), ethylene glycol tetraace-
tic acid (EGTA) (cat # E4378), paraformaldehyde (PFA)
(cat # P6148), dimethyl sulfoxide (DMSO) (cat # 472301)
and glutaraldehyde (cat # G-7776) were all purchased
from Sigma-Aldrich (St. Louis, MO, USA). EZ-Link Sulfo-
NHS-LC-biotin was from Pierce (Rockford, IL, USA). The
monoclonal antibody Ab9 used for immunoprecipitation
of Ab was purified from supernatants of the hybridoma
generated in mice by Biomatik Corporation (Ontario, ON,
Canada). The polyclonal antibody CT15 (against C-term-
inal 15 residues of APP) and the polyclonal antibody, 63G
(against mid region of APP) have been described pre-
viously [28,29]. The monoclonal antibody 6E10 (cat # SIG-
39300, recognizing 1- 17 of Ab sequence) was obtained
from Covance Research (Denver, CO, USA). Polyclonal
anti-sAPPb-WT antibody (cat # 18957) was purchased
from IBL Co. Ltd (Gunma, Japan). Monoclonal anti-Iba1-
AIF1 antibody (cat # MABN92) was purchased from Milli-
pore (Billerica, MA, USA). Polyclonal anti-TGF beta 1
antibody (cat # NBP1-67698) was purchased from Novus
Biologicals (Littleton, CO, USA). Mouse monoclonal anti-
body against beta-actin (cat # A00702) was purchased
from Genscript USA Inc. (Piscataway, NJ, USA). Second-
ary antibodies, such as peroxidase-conjugated AffiniPure
goat anti-mouse (Code # 115-035-146) and ant-rabbit
(code # 111-035-144) immunoglobulin Gs (IgGs), were
purchased from Jackson ImmunoResearch Laboratories
(West Grove, PA, USA). Anti-mouse IgG and anti-rabbit
IgG-agarose beads were from American Qualex Interna-
tional (San Clemente, CA, USA). ADAM10 and 17
enzymes, and the substrate for inhibition assays were pur-
chased from R&D Systems (Minneapolis, MN, USA; cat#:
936-AD-020, 930-ADB-010, ES010, respectively).
Quantitation of Ab, CTFs and sAPPs in 7WD10 cells
The methods for the generation and characterization of
CHO cells stably expressing APP751wt (7WD10 cells)
for the secretion of Ab into the conditioned medium
(CM) have been described previously [28,29]. To immu-
noprecipitate Ab, 7WD10 cells were grown in six-well
plates and were treated with BCNU at final concentra-
tions of 0, 0.5, 1.0, 5.0, 10.0 and 20.0 μM in duplicate
wells. After 48 hours, the CM was collected, centrifuged
to remove cell debris and immunoprecipitated overnight
using a monoclonal Ab9 antibody (recognizes 1 - 16
amino acids of Ab) to pull-down total Ab. After SDS-
PAGE electrophoresis using NuPAGE 4% to 12% bis-tris
gels, total Ab was detected by immunoblotting using a
mixture of 6E10/82E1 antibodies which reliably detects
total Ab as described previously [28,29]. The CM was
also immunoblotted to detect sAPPa (6E10), sAPPb
(anti-sAPPb-wt rabbit IgG from IBL America Ltd) and
sAPPtotal (63G) using the indicated antibodies. To detect
APP holoprotein and CTFs (CT15 antibody raised
against the last 15 amino acids of APP), the cells were
lysed using lysis buffer (1% Nonidet P-40) with complete
protease inhibitor mix (Sigma) and equal amounts of
proteins were loaded into each well and subjected to
SDS-PAGE electrophoresis. Following transfer onto poly-
vinylidene difluoride (PVDF) membranes, they were
blocked with 5% milk in Tris-buffered saline with Tween
(TBS-T) and incubated overnight with primary antibo-
dies followed by one to four hours of incubation with
horseradish peroxidase (HRP)-conjugated secondary anti-
bodies, such as monoclonal mouse anti-goat IgG light
chain or monoclonal mouse anti-rabbit IgG light chain.
The protein signals were detected using Super Signal
West Pico Chemiluminescent substrate (Pierce). Quanti-
tation of Western blot signals was done using Java-based
ImageJ software available freely from NIH.
APP turn-over and surface biotinylation experiments
Near confluent 7WD10 cells in duplicate wells were trea-
ted with BCNU at 10.0 mM concentration and after 24
hours, washed two times with cold PBS and incubated
with 2.0 mg/ml sulfo-NHS-LC-biotin in PBS, pH 8.0
under ultra-low shaking on ice in the cold room. After an
hour of incubation, cells were washed three times in PBS
and lysates were prepared using 1% Nonidet P-40 lysis
buffer containing complete protease mix as described
above. Biotinylated proteins were pulled-down by immu-
noprecipitation with anti-biotin antibody plus anti-
mouse agarose beads. The samples were subjected to
SDS-PAGE and APP was detected with CT15 antibody.
To assess the effect of BCNU on APP stability, cyclohexi-
mide experiments were done essentially as previously
described in our published papers [28,29]. Briefly,
7WD10 cells were incubated with cycloheximide at a
concentration of 100 mg/ml in PBS at 37°C in a CO2
incubator. Treated and untreated cells were harvested
and lysed at 0, 15, 30, 60, and 120 minutes. The lysates
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were processed to detect APP with CT15 antibody as
described above.
Measurement of activities of secretase enzymes
Enzyme activities were measured using partially purified
enzymes from mouse brain homogenates using commer-
cially available kits for BACE (cat # 565785, EMD Milli-
pore, a division of Merck KGaA, Darmstadt, Germany)
and g-secretase (cat # FP003, R&D Systems) according to
the manufacturer’s instructions. The fluorogenic substrate
used for BACE was glu-val-lys-met-asp-ala-glu-phe-lys,
and for g-secretase was NMA-GGVVIATVK (DNP)-
DRDRDR-NH2. The procedure briefly includes membrane
isolations from the mouse brains at 4°C by homogeniza-
tion using an extraction buffer (20 mM HEPES, pH 7.5; 50
mM KCl and 2 mM EGTA). Lysates were centrifuged at
800 g for 10 minutes to remove nuclei and large cell debris
in the pellet and the supernatants collected. The pellets
were re-homogenized and more supernatants were col-
lected in the same way. The resulting supernatants were
pooled and centrifuged at 100,000 g for 1 hour at 4°C. The
resulting membrane pellet was washed once in extraction
buffer and suspended in the same buffer plus 10% glycerol
and flash-frozen in liquid nitrogen and stored at -80°C
until used. The total protein concentrations in membrane
preparations were determined using the BCA method
(Pierce). Membranes were resuspended at 0.5 mg/ml con-
centrations in resuspension buffer and solubilized at 4°C
for one hour with end-over-end rotation. Following centri-
fugation at 100,000 g for one hour, the supernatants were
collected.
The assay mixture consisted of 50 ul of partially purified
enzyme preparation, 48 ul of 2 times reaction buffer
(20 mM HEPES, pH, 7.0; 150 mM of KCl; 2 mM EGTA;
1% (W/V) CHAPSO) and 2 ul of BACE or g-secretase sub-
strate. The mixture was incubated for two hours in the
dark and fluorescence was read at 320/420 nm for BACE
and 355/440 nm for g-secretase. Some samples also
included BACE or g-secretase specific inhibitors to con-
firm the specificity of enzyme activity. One negative con-
trol without lysate and another without substrate were
included. The positive control included was 2.0 ul of
recombinant BACE enzyme. The enzyme activity was cal-
culated per mg protein and was expressed as percentage
change in BCNU-treated samples from untreated controls.
ADAM10 and 17 inhibition assays followed the same
general protocol: 5 μL of 3x enzyme solution (3 and
30 nM) in assay buffer (10 mM HEPES, 0.001% Brij-35, pH
7.5) were added to solid bottom white 384 low volume
plates (Nunc cat# 264706). Next, 5 μL of test compounds
or pharmacological controls were added to corresponding
wells. After 30 minutes incubation at room temperature
(RT) the reactions were started by addition of 5 μL of 3x
solutions of substrate (30 μM). Fluorescence was measured
every 30 minutes for 2 hours using the multimode micro-
plate reader Synergy H4 (Biotek Instruments, Winooski,
VT, USA) using lexcitation = 324 nm and lemission = 405 nm.
Rates of hydrolysis were obtained from plots of fluores-
cence versus time, and inhibition was calculated using rates
obtained from wells containing substrate only (100% inhibi-
tion) and substrate with enzyme (0% inhibition). The IC50
value of the pharmacological control ((N-hydroxy-1-(4-
methoxyphenyl)sulfonyl-4-(4-biphenylcarbonyl)piperazine-
2-carboxamide, Calbiochem cat#: 444252) was also calcu-
lated to ascertain the assay robustness.
Cytotoxicity assays
As oncology drugs are generally cytotoxic, we wanted to
identify the minimal concentrations of BCNU necessary
for cytotoxicity. Neuro-2A (N2a) cells were incubated with
BCNU at final concentrations of 0, 0.1, 1.0, 5.0, 10.0, 20.0,
80.0 and 240.0 uM for 24 hours. To determine cell viabi-
lity, first we used the calorimetric 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) metabolic
activity assay using a cell growth determination kit (cat #
CGD-1, Sigma Aldrich) according to the manufacturer’s
instructions. Briefly, the supernatant was removed, cells
were washed two times with PBS and 20 μl of MTT solu-
tion (5 mg/ml in PBS) plus 100 μl of medium were added.
Following four hours of incubation at 37°C, the resulting
formazan crystals were dissolved in 100 μl of DMSO and
the absorbance was read at 570 nm within an hour using
the Smart Spec Plus spectrophotometer (Bio-Rad). Cells
treated with medium only served as controls.
To reproduce and confirm these results, we also mea-
sured cell viability using an in vitro toxicology assay kit
based on secretion of lactic dehydrogenase (LDH) (cat #
TOX7, Sigma Aldrich). The assay is based on reduction of
nicotinamide adenine dinucleotide (NAD) by LDH
enzyme into NADH which converts tetrazolium dye to a
colored compound that can be quantitated spectrophoto-
metrically. The procedure briefly is as follows: after 24
hours incubation of cells with BCNU at different concen-
trations, 50 μl of LDH assay lysis solution was added to
each well and further incubated at 37°C for 45 minutes.
The assay mixture was freshly prepared by adding equal
volumes of substrate, dye and cofactor; 50 μl of LDH assay
mixture was added to each of the 50 μl aliquots of the test
medium. The plates were sealed with aluminum foil to
protect from light and incubated for 30 minutes at 37°C.
The reaction was terminated by adding 10 μl of 1 N HCl
and the absorbance was measured at a wavelength of
490 nm.
Staining of amyloid plaques
APdE9 mice that overexpress both APP with Swedish
mutation and PS1 with ΔE9 deletion were used as a
robust mouse model of Alzheimer’s disease. All animal
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procedures were carried out strictly following the
National Institutes of Health’s ‘Guide for the Care and
Use of Animals’ and using the animal protocol as
approved (protocol # TPI-03-11) by the Torrey Pines
Institute’s Animal Care and Use Committee (IACUC).
BCNU, dissolved initially in DMSO and further diluted
in saline, was administered to mice daily by intraperito-
neal injections at 0.5 mg/kg body weight starting from
four months of age until six months of age for 60 days.
Age and genotype-matched control mice received vehi-
cle injections for the same period of time. Following the
treatment period, mice were anesthetized by isoflurane
and perfused using a mixture of 4% PFA and 0.02% glu-
taraldehyde in PBS. After 72 hours, the brains were
dehydrated using sucrose gradient. Brains were frozen in
optimal cutting temperature (OCT) solution and coronal
sections of 16 μM thickness were cut by cryostat at
-19°C to 21°C and transferred to superfrost slides. The
slides were rinsed twice with distilled water for five min-
utes. The slides were then immersed in 1% thioflavin S
solution prepared in 50% ethanol for five minutes and
then differentiated in 70% ethanol for five minutes,
rinsed again twice in water for five minutes and cover-
slipped with Sure mount (EMS) mounting media and
held at 4°C until they were imaged. Images were cap-
tured using a Zeiss Examiner D1 microscope. All images
were acquired at the same exposure and were automati-
cally aligned using the stitching tool in the Axiovision
LE software. Once acquired, all images were opened in
ImageJ and were normalized; the threshold was set for
each image using the histogram mean at the same stan-
dard deviation. Each image was adjusted to the thresh-
old and set to scale in pixels. The parameters measured
include the area, integrated density, perimeter, and fer-
et’s diameter for each plaque. To help eliminate back-
ground the particle size pixel was set at 30-infinity pixel.
To quantify plaques, the brain level of cut sections was
fixed for all mice at the region of the motor cortex and
hippocampus corresponding to the starting section at
interaural 2.34 mm and Bregma -1.46 mm of ‘The Mouse
Brain Atlas’ by George Paxinos and Keith Franklin.
A fixed thickness of 16 μM coronal sections at regular
intervals was maintained in all animals. The amyloid pla-
ques were quantified from throughout the sections from
five sections per mouse and mean values were generated
for each mouse. Pictures were montaged and, for quanti-
fication by image J software, the color images were con-
verted in to HSV format and 8-bit channels. Plaques
were quantified in an unbiased manner by an investigator
blind to the treatment nature of the samples. Plaque bur-
den was calculated as the area occupied by the plaques
divided by the total brain region area. The data are
expressed as percent change in means from the controls.
Quantitation of Ab40 levels in the brain by ELISA
Ab40 levels in the brain extracts were determined by sand-
wich ELISA. Briefly, the wet mass of the brain was weighed
and homogenized thoroughly in cold 1% CHAPSO/PBS
with protease inhibitors. The homogenate was ultra-centri-
fuged at 100,000 g for 60 minutes. The samples were
further diluted to 40-fold and stored on ice until use. The
Ab standard (Bachem) was dissolved in hexafluoroisopro-
panol at 1 mg/ml, sonicated and dried under nitrogen. The
dried Ab40 was resuspended in DMSO, separated into ali-
quots and frozen at -80°C. The rest of the protocol is
exactly as described previously from our laboratory [28].
The quantity of Ab40 in each sample was measured in
quadruplicate. Total protein concentrations were deter-
mined using the BCA assay (Pierce).
Iba1 I mmunohistochemistry
Brain sections (18 um) from saline- and BCNU-treated
mice were washed two times with PBS 1X for five minutes.
Antigen retrieval was carried out by immersing slides in
10 mM citric acid (pH 6.0) for 10 minutes at 90°C.
Sections were washed three times with PBS 1X for five
minutes and incubated in blocking solution (10% normal
goat serum, 1% BSA, 0.1% Triton X-100 in PBS 1X) for
one hour at RT. The sections were incubated overnight
with anti-Iba1/ALF1 mouse monoclonal antibody (Milli-
pore) in blocking solution (1:200) at 4°C. After washing
three times in PBS 1X for 5 minutes, the sections were
incubated with Alexa Fluor® 568 goat anti-mouse IgG
(Invitrogen) in blocking solution (1:500) at RT for two
hours in the dark. Finally, slides were washed three times
with PBS for five minutes, covered with mounting medium
for fluorescence with 4’,6-diamidino-2-phenylindole
(DAPI) (Vector Laboratories) and sealed with nail clear.
Sections were visualized in a fluorescence microscope
(Axio Examiner D1) and a confocal microscope (Nikon
90i, scan head-C1 SHS, Melles Griot laser system). Micro-
glia were counted in a defined area of the motor cortex
and hippocampus (CA3) using the Image-Pro Plus (Media
Cybernetics) software package. Positive cells were defined
as those whose nuclei and processes were evidently stained
for Iba1 and whose nuclei were co-localized with DAPI.
Quantitation of BCNU drug levels in the brain
Two sets of three mice each were injected with BCNU at
4 mg/kg body weight and euthanized after either 5 or
20 minutes. The brains were rapidly removed, frozen and
weighed before being homogenized in 250 μL of Dulbec-
co’s PBS (dPBS), immediately followed by 750 μL of acet-
onitrile. The samples were spun for 10 minutes at
10,000 rpm at 4°C. The supernatant was removed and
the samples were dried for two hours. The pellets were
left at 4°C overnight, and on the following day samples
Hayes et al. BMC Medicine 2013, 11:81
http://www.biomedcentral.com/1741-7015/11/81
Page 5 of 22
were reconstituted in 30% acetonitrile, vortexed, and
spun at 13,000 rpm for five minutes at 4°C. To assess sta-
bility of BCNU in the blood, blood samples were col-
lected from several mice after anesthesia with isoflurane
and 200 μL of blood was mixed with 8 μL of EDTA (final
concentration 1.5 mg/mL) and about 100 μg of BCNU in
4 μl. The mixture was allowed to stand in a 37°C water
bath for 0, 5, 10, 15 and 30 minutes. After the chase time,
600 μL of 100% acetonitrile was added to the sample. The
samples were spun at 3,000 g for five minutes and
the supernatant was collected. Each sample was made in
triplicate, with the exception of the 0 minute blood
which was done in duplicate. The blood samples were
dried for approximately three hours. The pellet was
reconstituted using 100 μL of 30% acetonitrile, vortexed
and spun at 13,000 g for five minutes. The samples were
transferred to shelf pack vials and run on the UV mass
spectrometer. Similarly, to assess BCNU stability in the
brain homogenates, three mice were anesthetized with
isoflurane, perfused with dPBS and their brains collected.
Brains were homogenized in 250 μL of dPBS and 200 μL
of brain homogenate was incubated with 100 μg of
BCNU for 1, 15, or 30 minutes at 37°C. After the chase
time, 750 μL of 100% acetonitrile was added to the sam-
ple. The rest of the procedure was similar to the samples
prepared for blood. All analyses were performed in
triplicate.
The samples were then run on the UV mass spectro-
meter. The liquid chromatography system (Shimadzu,
Kyoto, Japan) consisted of a LC20AD binary solvent deliv-
ery pump, a DGU-20A5 degasser, CTO-20A column oven
and a SPD-M20A photodiode array detector. Chromato-
graphic separation was carried out on a C-18 reverse
phase column (Luna 50 μ, 100 Å, 50 × 4.6 mm) fitted with
a C-18 reverse phase guard cartridge (Phenomenex, 4 ×
3.00 mm) and BCNU was eluted using a gradient of sol-
vents A (0.1% formic acid in water) and B (0.1% formic
acid in acetonitrile) at 0.5 mL/minute flow rate. The gradi-
ent was 5% to 65% B over 20 minutes, 65% to 95% B over
one minute, and kept for two minutes and restored to 5%
B in one minute followed by re-equilibration for five min-
utes. The peak for BCNU was monitored at 280 nm by
injecting 5 μL of the sample.
Statistical analysis
The signal intensities of immunoblots of the samples trea-
ted with BCNU in CHO cells as well as plaque burden in
the mouse brain were quantified using publicly available
Java-based ImageJ software developed at the National
Institutes of Health. All data were analyzed by Student’s t
test using Instat3 software (GraphPad Software, San
Diego, CA, USA). We used a two-tailed P value assuming
populations may have different standard errors. The data
for dose-response experiments were analyzed by analysis
of variance (ANOVA) followed by either Dunnett or Bon-
ferroni multiple comparison tests. The data were consid-
ered significant only if the P < 0.05, * indicates P < 0.05, **,
P < 0.01 and ***, P < 0.001.
Results
BCNU decreases Ab levels dose-dependently in CHO cells
Anecdotal observations in nursing homes that cancer sur-
vivors were less likely to be diagnosed with AD which was
confirmed in multiple studies [25,26,30] strongly suggest
an inverse relationship between cancer and AD. This com-
pelling evidence led us to firmly believe that oncology
drugs might be helpful in AD. Therefore, we screened a
library of all the FDA-approved oncology drugs totaling 89
compounds obtained from NCI/NIH [27] at a concentra-
tion of 10.0 μM to determine their effects on Ab levels by
immunoprecipitation of Ab in the CM and Western blot-
ting. Interestingly, BCNU strongly decreased Ab levels in
CHO cells in the initial screens (Figure 1A). Subsequent
dose-response experiments confirmed that BCNU induced
decreased Ab levels in CHO cells (Figure 1B &1C). To test
the effect of different concentrations of BCNU, CHO cells
stably expressing APP751WT (7WD10) were treated for
48 hours and the CM were immunoprecipitated with Ab9
antibody which recognizes an epitope within 1-16 amino
acids of Ab peptide. This was followed by a Western blot
detection of Ab using the 6E10/82E1 mixture of antibodies
which we have previously used for consistent detection of
total Ab species [28,29]. Exposure of 7WD10 cells to
BCNU decreased the secretion of Ab starting at 5.0 μM by
39% (P < 0.05), 10.0 μM by 51% (P < 0.01) and 20 μM by
63% (P < 0.01) compared to cells treated with a structural
analog as controls (Figure 1B and 1C). Thus, increasing
the concentration of BCNU revealed a dose-dependent
decrease in Ab levels, without altering the level of
the holoprotein at any of the concentrations tested. These
results demonstrate that BCNU inhibits b/g-secretase
mediated APP cleavage of WT APP.
In an effort to identify more potent carmustine analogs,
we synthesized 12 carmustine structural derivatives and
screened them for their effect on Ab levels. The derivatives
tested include 1-(2-chloroethyl)-3-hexylimidazolidin-2-one
(C11H21ClN20; MW, 232.7502), 1-(2-chloroethyl)-3-(3-iso-
propylphenylimidazolidin-2-one (C14H19ClN20; MW,
266.7665), 1, 3-bis(2-chloroethylimidazolidin-2-one
(C7H12Cl2N20; MW, 232.7502), 1-(2-chloroethyl)-3-(3-
phenylimidazolidin-2-one (C11H13ClN20; MW, 224.6867),
1-(2-bromoethyl)-3-(2-chloroethylimidazolidin-2-one
(C7H12BrClN20; MW, 255.5400), 1-(2-chloroacetyl)-3-(2-
chloroethyllimidazolidin-2-one (C7H10Cl2N202; MW,
225.0725), 1-(2-chloroethyl)-3-phenylimidazolidin-2-
thione (C11H13ClN2S; MW, 240.7523), phenyl ethyla-
mine (C19H25N3O; MW, 311.20), cyclopentyl amine
(C13H25N3O; MW, 239.20), butyl amine (C11H25N3O;
Hayes et al. BMC Medicine 2013, 11:81
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Figure 1 BCNU decreases Ab and CTF levels in CHO cells stably expressing APP751WT (7WD10 cells). A) An initial screening of a library
of oncology drugs used at 10.0 μM identified carmustine (BCNU) as a potential anti-Ab drug, while drugs such as 1 and 4 increased Ab levels.
The cells were exposed to the drugs for 48 hours and the conditioned media were immunoprecipitated for Ab and detected by immunoblots.
B) 7WD10 cells were incubated with different concentrations of BCNU for 48 hours and the conditioned media were immunoprecipitated for Ab
and detected by immunoblots. C) Quantitation of Ab levels by ImageJ revealed decreased Ab levels to 61% (P < 0.05) at 5 μM, 49% (P < 0.01) at
10 μM and 37% (P < 0.01) at 20 μM compared to controls. D) The lysates were used to detect c-terminal fragments (CTFs) and APP as well as
actin as a loading control. E) CTF levels were also significantly decreased to 44% (P < 0.05) at 5 μM, 30% (P < 0.01) at 10 μM and 43% (P < 0.05)
at 20 μM compared to controls. F) The conditioned media from B was subjected to immunoblotting to detect different species of sAPPs. G)
sAPPa levels were increased to 167% (P < 0.01) at 0.5 uM, 186% (P < 0.05) at 1 uM, 204% (P < 0.01) at 5 uM and 152% (P < 0.05) at 10 uM
compared to untreated cells. H) sAPPtotal levels were increased to 159% (P < 0.05) at 5 μM, 172% (P < 0.01) at 10 μM and 170% (P < 0.01) at 20
μM in BCNU treated cells compared to controls. For all samples, n = 4 ± SEM. *, P < 0.05, **, P < 0.01 versus control by analysis of variance
(ANOVA) followed by post-hoc test by Dunnett multiple comparisons. Ab, amyloid b; APP, Alzheimer’s precursor protein; BCNU, 1, 3 bis (2-
chloroethyl)-1-nitrosourea; CHO, Chinese hamster ovary; SEM, standard error of the mean.
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MW, 215.20), piperidine (C13H25N3O; MW, 239.20) and
morpholine (C11H21N3O3; MW, 243.16). None of the deri-
vatives were as potent as BCNU.
BCNU decreases CTF levels dose-dependently in CHO cells
To quantify APP-derived CTF levels, lysates were prepared
from the same cells that were used for Ab quantitation
after treatment with different concentrations of BCNU.
CTFs were detected by Western blotting using CT15 anti-
body. Similar to Ab levels, CTF levels were also signifi-
cantly decreased at 5.0 μM (55%, P < 0.05), 10.0 μM (70%,
P < 0.01) and 20.0 μM (56%, P < 0.05) compared to
untreated controls (Figure 1D and 1E). Thus, except for
the first two lower concentrations, BCNU significantly
decreased APP processing and CTF production, starting
from 5.0 μM. These changes occurred without alterations
in APP holoprotein which was also detected by the CT15
antibody. The decreased CTF levels are consistent with
decreased Ab levels by BCNU and indicate that BCNU
decreases amyloidogenic processing of APP in CHO cells.
BCNU significantly increases levels of sAPPa and
sAPPtotal but not sAPPb
To obtain an overall picture of APP metabolism under
BCNU treatment, we further quantified the levels of
secreted large extracellular N-terminal domain truncated
protein at the a-site (sAPPa) or at the b-site (sAPPb) as
well as levels of sAPPtotal from the same CM used for Ab
quantification. More than a one-fold increase was noted
for sAPPa levels at some concentrations of BCNU applied
for 48 hours, although we did not notice a strict dose-
dependent increase in sAPPa levels. The secretion of
sAPPa was increased to 167% at 0.5 μM (P < 0.01), 186%
(P < 0.05) at 1.0 μM, 204% (P < 0.01) at 5.0 μM and 152%
(P < 0.05) at 10.0 μM (Figure 1F and 1G). For some
unknown reason, sAPPa levels were not altered at the
highest concentration of 20.0 μM tested, although Ab
levels were significantly decreased. The maximum increase
(204%) was noted at 5.0 μM concentration. Similarly, the
levels of sAPPtotal were increased by 159% (P < 0.05) at
5.0 μM, 172% (P < 0.01) at 10.0 μM and 170% (P < 0.01)
at 20.0 μM in BCNU-treated cells (Figure 1F and 1H). On
the other hand, there were no significant alterations in the
levels of sAPPb at any of the BCNU concentrations tested.
The sAPPa levels were detected using 6E10 antibody
which recognizes an epitope within the 1-17 amino acid of
the Ab domain of APP. sAPPtotal was detected by the
63G antibody whose epitope lies within the mid region of
APP. Taken together, decreased levels of Ab and CTFs
and increased release of sAPPa and sAPPtotal in the CM
clearly indicate that BCNU may decrease amyloidogenic
processing of APP by increasing a-secretase mediated
cleavage of APP thereby reducing the APP substrate avail-
able for cleavage by BACE enzyme.
BCNU increases immature APP at the cell surface
As endocytosis of surface APP is required for Ab genera-
tion [31,32], we next examined whether BCNU treatment
altered surface levels of APP. To do this, all surface pro-
teins were labeled with biotin and immunoprecipitated
with antibiotin antibody. Results showed that BCNU-
treated cells accumulated immature APP by more than
one-fold at the cell surface compared to untreated cells
(P < 0.001), while there was no change in the surface
levels of mature APP (Figure 2A and 2B). Next, to test
whether decreased amyloidogenic processing of APP is
due to changes in turn-over of APP, we performed cyclo-
heximide chase experiments. Confluent 7WD10 cells in
six-well plates treated with or without BCNU were incu-
bated with 100 mg/ml of cycloheximide to inhibit de
novo synthesis of APP. This was followed by quantitation
of steady state levels of APP holoprotein by Western
blots at different time points up to two hours based on
our previous experience that the calculated half-life of
APP was about one hour [28]. The results did not reveal
significant differences in the levels of APP at any of the
time points tested between untreated and BCNU-treated
cells (Figure 2C). This suggests that BCNU does not
affect the half-life of APP and its stability. The decreased
levels of Ab and CTFs induced by BCNU treatment,
therefore, might result from increased immature APP at
the cell surface leading to reduced endocytosis of APP
which is necessary for cleavage of APP by secretases for
Ab production [31,32].
BCNU does not inhibit secretases
APP is cleaved by sequential actions of b- and g-secre-
tases to release Ab and, therefore, compounds that
reduce Ab generation can be expected to inhibit secre-
tases. Therefore, we tested whether BCNU inhibits any
of the secretases. To our surprise the activities of both
b- and g-secretases were not affected by BCNU even at
concentrations as high as 40 μM of BCNU (Figure 3A).
Similarly, we did not notice any change in the activities
of ADAM 17 or ADAM 10 (Figure 3B), which cleaves
APP at the a-site. Thus, BCNU appears to decrease Ab
generation independent of secretases, probably by sim-
ply altering the trafficking of APP.
Cytotoxicity of BCNU measured by LDH release and
MTT reduction
The cytotoxicity of BCNU was determined by two inde-
pendent enzyme-based assays by colorimetric detection
using neuron-derived neuro-2a (N2a) cells. The LDH
release assay revealed BCNU was nontoxic up to 20 μM
and was toxic only at 80 μM (69.5%, P < 0.01) and 240 μM
(49%, P < 0.01) (Figure 4B). To confirm these results by
another method, we used CM from the cells incubated
with different concentrations of BCNU to quantify the
Hayes et al. BMC Medicine 2013, 11:81
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Figure 2 BCNU increases surface levels of immature APP. A) Surface biotinylation and biotin immunoprecipitation experiments showed
significantly increased surface levels of immature APP in BCNU-treated 7WD10 cells compared to untreated cells. B) Quantitation of the signal in
A) revealed increased surface to total APP levels for immature APP by 184% but the levels of mature APP were unaltered. C) Treatment of
7WD10 cells with BCNU at 10.0 uM concentration followed by cycloheximide chase at indicated time points did not alter APP half-life or
stability. For all samples, n = 4 ± SEM. ***, P < 0.001 versus controls by t test. APP, Alzheimer’s precursor protein; BCNU, 1, 3 bis (2-chloroethyl)-1-
nitrosourea; SEM, standard error of the mean.
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Figure 3 BCNU does not alter the activities of secretases. A) Partially purified b- and g-secretase enzyme complexes from mouse brain
homogenates were used to detect the activity of secretases using specific fluorogenic substrates. BCNU up to 40 μM did not inhibit the
activities of either b- or g-secretases. B) The activities of both ADAM17 and ADAM10 (a-secretase) were also not affected by BCNU at any of the
concentrations tested. BCNU, 1, 3 bis (2-chloroethyl)-1-nitrosourea.
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reduction of the MTT substrate. The MTT reduction
assay reproduced the results of the LDH assay in that
BCNU was non-toxic up to a concentration of 20 μM.
However, BCNU incubation at 80 μM (50%, P < 0.01) and
240 μM (45%, P < 0.01) was significantly toxic at each con-
centration (Figure 4A). Thus, it is interesting to note that
BCNU is toxic to the neuronal cell line only at high con-
centrations but not at concentrations that decreased Ab
levels.
Chronic BCNU administration decreases plaque burden
in mice
Although BCNU decreased Ab production in cell cul-
tures, amyloid plaques in the brain are more relevant to
neurodegeneration in AD. Therefore, to verify whether
decreased amyloidogenic processing of APP by BCNU
observed in cell cultures is translated in vivo into
decreased plaque burden, mice overexpressing APP with
Swedish mutation and PS1 with ΔE9 deletion were used
as a robust mouse model for Ab plaques (APdE9) as
these mice develop a modest amount of amyloid plaques
as early as six months of age. Overall plaque burden was
calculated as the ratio of ‘the area occupied by plaques
to the total region area’, which was clearly decreased by
about 81% (P < 0.01) in BCNU-treated mice compared
to saline-treated mice (Figure 5A, B and 5C). A repre-
sentative histology section for saline- or BCNU-treated
mice is shown in Figure 5A and 5B at comparable brain
levels. The total plaque numbers were reduced only by
26% (Figure 5D, P < 0.05). However, when the plaques
were counted based on their size, those plaques which
measured more than 1.0 square micron decreased by
39% (Figure 5E, P < 0.05) and those measuring above
3.0 square microns decreased by 41% (Figure 5F, P <
0.05) in the BCNU-treated mice compared to the saline-
treated mice. Highly decreased plaque burden and a
modest reduction in plaque numbers in BCNU-treated
mice indicates that BCNU decreases the severity of pla-
ques by reducing larger plaques. The decreased amyloid
plaque burden following chronic BCNU administration
in mice is consistent with decreased amyloidogenic pro-
cessing of APP and Ab levels observed in cell cultures
(Figure 1A, B and 1C).
BCNU decreases levels of Ab40 and CTFs and increases
sAPPa in mouse brains
To test whether the decrease in amyloid plaques by BCNU
was due to a decrease in Ab, we quantified the levels of
Ab40 in the mouse brains by sandwich ELISA using Ab
specific antibodies. Exposure of BCNU even just for two
months resulted in a 75% reduction in the levels of Ab40
(Figure 6B), which correlates well with the amount of
reduction in amyloid plaques. Similar to the effect in cell
cultures, CTF levels were also reduced in the brains after
BCNU treatment by 39% (P < 0.01) (Figure 6C). Conver-
sely, the levels of sAPPa were increased by 45% (P < 0.01)
(Figure 6D). Thus, BCNU-induced changes in APP meta-
bolites observed in cell cultures were confirmed in vivo in
the mouse brains.
BCNU is rapidly metabolized in mice
In order to correlate the drug concentrations in the brain
that are required to reduce amyloidogenic processing of
APP and plaque burden, we quantified BCNU levels in
the brain by liquid chromatography with UV detection.
At least three mice were tested for each of 5 and 20 min-
ute time points following tail vein injection. Surprisingly,
we failed to detect any BCNU at either time point. Direct
incubation of BCNU in the blood and brain homogenates
confirmed that BCNU was rapidly degraded with no
trace of the compound in the brain homogenates within
30 minutes (Figure 7A), although BCNU could be
detected up to 30 minutes in the blood (Figure 7B).
These results suggest that BCNU is rapidly metabolized
and the biological effect exerted on Ab levels could result
from the action of one of the metabolites. In fact, the dis-
tribution and clearance of BCNU in both human and ani-
mals have been extensively studied. BCNU is a very
unstable compound which undergoes both in vitro and in
vivo spontaneous degradation to isocyanate and the
chloroethylodiazohydroxide ion, which then is degraded
to the chloroethylocarbonic ion and others [33,34]. Care-
ful analysis of the chromatograms of brain homogenates
revealed the presence of several metabolites, labeled A to
E, which we could identify in addition to several others
which we could not identify (Figure 8A). We detected
only a very small peak for the parent compound, BCNU,
labeled F in the chromatogram (Figure 8A). The names
and chemical structures of identified metabolites with
their molecular weights are shown in Figure 8B. Such
metabolites might actually be responsible for decreasing
Ab levels and plaque burden.
BCNU suppresses microglial activation
In order to understand whether BCNU-mediated
decreased plaque burden results from an increased num-
ber of activated microglia as previously shown for some
oncology drugs, we quantified the number of activated
microglia by staining brain sections with anti-Iba1 anti-
body. On the contrary, as shown in Figure 9A and 9C,
chronic BCNU treatment resulted in a lower number of
Iba1-positive microglia in the hippocampus (30%, P <
0.05). Similarly we observed a 44% (P < 0.01) lower num-
ber of Iba1-positve microglia in the motor cortex of
BCNU-treated mouse brains as compared to saline-treated
controls (Figure 9B and 9C). Thus, BCNU, in contrast to
other oncology drugs, reduces microglial activation. This
may even have a positive effect on the brain since activated
Hayes et al. BMC Medicine 2013, 11:81
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Figure 4 BCNU is cytotoxic only at high concentrations in Neuro-2a (N2a) cells. A) LDH release was measured as an indicator of
cytotoxicity after incubation with different concentrations of BCNU as indicated. BCNU was not toxic up to 20 μM and significant cytotoxicity
was observed only at 80 μM (P < 0.01), and120 μM (P < 0.01). B) The MTT reduction assay also indicated significant toxicity only at 80 μM (69%,
P < 0.01) and 240 μM (48.7%, P < 0.001) but BCNU was nontoxic up to 20 μM. For all samples, n = 4 ± SEM. **, P < 0.01versus untreated
controls by analysis of variance (ANOVA) followed by post-hoc test by Dunnett multiple comparisons. BCNU, 1, 3 bis (2-chloroethyl)-1-
nitrosourea; LDH, lactate dehydrogenase; MTT, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide.
Hayes et al. BMC Medicine 2013, 11:81
http://www.biomedcentral.com/1741-7015/11/81









































   



















   
   
















Figure 5 Chronic BCNU administration decreases amyloid plaque burden in mice. APdE9 mice were treated daily by intraperitoneal
injections with BCNU starting from four months to six months of age for 60 days. Amyloid plaques were stained by thioflavin S in coronal brain
sections. A) A representative section with amyloid plaques in vehicle-treated mice at six months of age is shown. B) A representative section of
brain showing decreased amyloid plaques in mice treated with BCNU is shown. C) Quantitation by ImageJ analysis showed decreased plaque
burden by 81% (P < 0.01) when compared to vehicle-treated APdE9 mice. D) The total number of plaques was reduced by 26% (P < 0.05). E)
Plaques measuring more than 1.0 square micron were reduced by 39% (P < 0.05). F) Plaques measuring more than 3.0 square microns
decreased by 41% (P < 0.05). In each group, n = 6, ± SEM. *, P < 0.05, **, P < 0.01 in BCNU-treated APdE9 mice versus vehicle-treated APdE9
mice by student’s t test. BCNU, 1, 3 bis (2-chloroethyl)-1-nitrosourea; SEM, standard error of the mean.
Hayes et al. BMC Medicine 2013, 11:81
http://www.biomedcentral.com/1741-7015/11/81
Page 13 of 22
microglia is pro-inflammatory and may lead to
neurodegeneration.
BCNU increases transforming growth factor b levels
In a study using mRNA differential display, BCNU has
been shown to increase the expression of a gene encod-
ing the latent transforming growth factor-binding protein
1 (LTBP-1) by three-fold suggesting that BCNU might
increase transforming growth factor-b1 (TGF-b1) signal-
ing [35], which is known to play a pivotal role in APP
metabolism. Therefore, to understand the possible mole-
cular mechanism for the reduced amyloidogenic proces-
sing of APP by BCNU, we quantified the levels of TGFb























   













   







   
















Figure 6 Chronic BCNU administration alters APP metabolites in the mouse brain. Mice were treated as in legends to Figure 5.
A) Immunoblots showing APP (long exposure, LE and short exposure, SE), CTFs, sAPPa and actin as loading control. B) Quantification of Ab by
sandwich ELISA revealed robust reduction of Ab40 by 75% (P < 0.01) in BCNU-treated brains compared to saline-treated mice. C) Quantification
of CTFs also revealed significant reductions by 39% (P < 0.05) in BCNU-treated mouse brains. D) sAPPa levels were increased by 45% (P < 0.05)
in BCNU-treated mice. In each group, n = 5, ± SEM. *, P < 0.05, **, P < 0.01 in BCNU-treated APdE9 mice versus vehicle-treated APdE9 mice by
student’s t test. Ab, amyloid b; APP, Alzheimer’s precursor protein; BCNU, 1, 3 bis (2-chloroethyl)-1-nitrosourea; CTFs, c-terminal fragments; SEM,
standard error of the mean.
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A. Carmustine in brain homogenate  
B. Carmustine in blood  
Figure 7 BCNU is relatively unstable in tissues. A) Incubation of BCNU in mouse brain homogenates showed intact BCNU only up to 15
minutes, but at 30 minutes, there was no trace of BCNU. B) Intact BCNU, however, could be detected in the blood for up to 30 minutes. BCNU,
1, 3 bis (2-chloroethyl)-1-nitrosourea.
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Figure 8 Chloro isotopic distribution of the main metabolites identified in the brain homogenates after BCNU administration.
A) Chromatogram showing distribution of BCNU metabolites, labeled A to F with their molecular weights. B) Chemical structures of the
identified metabolites, A to F. BCNU, 1, 3 bis (2-chloroethyl)-1-nitrosourea.
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Figure 9 The number of activated microglia is reduced in both the hippocampus and motor cortex in BCNU-treated mouse brains.
A) Iba1 positive activated microglia (red) in the CA3 region of the hippocampus shown in saline- or BCNU-treated mouse brains. The nuclei
were stained with DAPI (blue) and the merged images (yellow) show microglia positive for Iba1, which were counted. B) Iba1 positive activated
microglia in the motor cortex. The magnification and the scale bars are indicated. The inset in both A and B is to show an enlarged microglia
positive for both DAPI and Iba1. C) Quantification showed 30% (P < 0.05) and 44% (P < 0.01) reduced numbers of activated microglia in the
hippocampus and motor cortex, respectively. All values are mean ± SEM, n = 5 in each group. *, P < 0.05, **, P < 0.01 in BCNU-treated APdE9
mice versus saline-treated APdE9 mice by student’s t test. BCNU, 1, 3 bis (2-chloroethyl)-1-nitrosourea; DAPI, 4’,6-diamidino-2-phenylindole; SEM,
standard error of the mean.
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cells were treated with different concentrations of BCNU.
Interestingly, TGFb levels were increased at 10.0 μM
(92%, P < 0.001) and 20.0 μM (73%, P < 0.01) compared
to untreated cells (Figure 10A and 10B). TGFb levels
were also significantly increased in the lysates at the
same concentrations of 10.0 μM (149%, P < 0.05) and
20.0 μM (154%, P < 0.01). The increased levels of TGFb
at the higher concentrations of BCNU are consistent
with decreased Ab levels at these concentrations.
Discussion
In this study, we have shown for the first time that
BCNU treatment can reduce amyloidogenic processing
of APP and Ab generation in cell cultures as well as in
a mouse model of AD. Although BCNU is known to be
a cytotoxic compound, it reduced Ab levels at non-toxic
concentrations. Two other oncology drugs have recently
been shown to significantly reduce Ab generation. Ima-
tinib (Gleevec) has been shown to reduce Ab by 50% at
10.0 μM concentration [36,37], similar to the magnitude
observed for BCNU in the present study, but the advan-
tage of BCNU is that it can pass through the BBB [38],
while Gleevec cannot [39]. Bexarotene, another oncology
drug, reduced amyloid plaques by 50% within 72 hours
after oral administration [40]. Although BCNU reduced
plaque burden by 81%, much more than did bexarotene,
it took two months of intraperitoneal administration
unlike bexarotene which rapidly cleared within a few
days of oral treatment. Thus, BCNU falls between Glee-
vec and bexarotene as a favorable Ab reducing drug.
It is noteworthy that BCNU decreased Ab levels from
CHO cells stably expressing APP751WT (7WD10 cells),
as the majority of cases of sporadic AD patients carry
wild-type APP. Thus, BCNU decreased Ab generation
from both the predominantly neuronal form, APP695, as
well as the non-neuronal form, APP751, considering the
results in 7WD10 cells as well as mouse brains. Wild-type
APP and APP with Swedish mutation are known to be
processed and trafficked differently. The most important
observation that we made was the increased ratio of
mature APP versus immature APP at the cell surface. The
molecular mechanisms that regulate APP maturity, traf-
ficking and Ab generation are complex. Newly synthesized
immature APP in the endoplasmic reticulum (ER) is first
N-glycosylated at the ER and after its exit undergoes
O-glycosylation at the Golgi complex attaining maturity.
In the secretory pathway mature APP is then sorted to the
plasma membrane where it undergoes endocytosis, a
necessary step for Ab production [31,32]. Thus, BCNU
reduces Ab generation probably by reducing endocytosis
of APP from the cell surface. But Ab can also be produced
in the secretory pathway. If APP undergoes a-cleavage
presumably in the secretory pathway in the trans-Golgi
network, it can drastically reduce Ab generation. Increased
sAPPa levels in the present study also suggests that BCNU
might influence Ab generation through increased a-secre-
tase mediated processing of APP. Decreased Ab levels
induced by BCNU may be a cumulative effect of both
pathways. Interestingly, several pharmacological agents
have been shown to reduce Ab generation by attenuating
APP maturity. For example, protein kinase A (PKA) inhi-
bitors have been shown to reduce Ab production by accu-
mulating immature APP [41]. Inhibitors of acyl-coenzyme
A cholesterol acyl transferase (ACAT) also reduced Ab
production by decreasing the ratio of mature to immature
APP [42]. Similarly, zinc [43] and O-glycosylation inhibi-
tors [44], both of which retarded APP maturation, also
reduced Ab generation. Since BCNU did not affect the
activities of any of the secretases, reduced Ab generation
most likely results from altered trafficking of APP due to
accumulation of immature APP. Protein overexpression
studies also provide indirect evidence that maturity and
trafficking of APP to the cell membrane affects Ab pro-
duction. Overexpression of growth arrest-specific 1 gene
also reduces Ab generation by inhibiting glycosylation of
APP thereby enhancing accumulation of immature APP in
the plasma membrane [45]. Collectively, these data pro-
vide compelling evidence that BCNU decreases Ab pro-
duction by retarding APP maturation thereby altering its
trafficking and cleavage. It is also possible that BCNU
decreased Ab levels through the TGFb pathway. Genetic
polymorphisms at +10 CC genotype on TGFb has been
shown to be associated with reduced serum levels of
TGFb in mild cognitive impairment (MCI) patients later
diagnosed as AD [46], and to increase the risk of develop-
ing late-onset AD [47]. Overexpression of TGFb in the
transgenic mouse models also reduces Ab generation and
plaque burden [48]. Thus, increased TGFb levels in both
the CM and lysates by BCNU are consistent with these
data. The mechanism by which BCNU reduces Ab and
plaque burden might be mainly through its effect on intra-
cellular trafficking and maturation of APP. Also, unlike
other oncology drugs, BCNU reduced the number of
microglia, ruling out the possibility that microglia are
responsible for clearing amyloid plaques. One limitation of
our study is that we did not co-stain microglia with an
anti-Ab antibody to stain amyloid plaques. The reduced
number of microglia may be related to the decreased amy-
loid load. Since we did not co-stain, we cannot conclude
that decreased microglia correlate with decreased plaque
burden. Another limitation of our study is that we did not
study the effect of short-term drug exposure on either
amyloid plaques or microglia. Thus, after short-term drug
treatment microglia numbers may be increased, but we do
not have data to support this idea.
In cancer patients, BCNU is administered at 200 mg/m2
every six weeks and since the body surface area in humans
is 1.6, the total dose administered is about 320 mg/person
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Figure 10 BCNU increases TGFb protein levels in 7WD10 cells. A) Cells were treated with BCNU at different concentrations as indicated and,
after 48 hours, the conditioned media (CM) as well as lysates were immunoblotted to detect TGFb protein. B) ImageJ quantitation revealed
significantly increased TGFb protein levels at 10.0 μM (73%, P < 0.01) and 20.0 μM (92%, P < 0.001) in the CM. Similarly in the lysates TGFb levels
were increased at the same concentrations of 10.0 μM (149%, P < 0.05) and 20.0 μM (154%, P < 0.01). For all samples, n = 4 ± SEM. *, P < 0.05,
**, P < 0.01, ***, P < 0.001versus untreated controls by analysis of variance (ANOVA) followed by post-hoc test by Dunnett multiple comparisons.
BCNU, 1, 3 bis (2-chloroethyl)-1-nitrosourea; SEM, standard error of the mean; TGFb, transforming growth factor b.
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(or approximately 4 mg/kg body weight), an equivalent of
300 μM in an adult. The major limiting factor of BCNU is
its toxicity, particularly hepatic and pulmonary fibrosis.
Therefore, to avoid systemic toxicity, patients with solid
brain tumors are implanted with BCNU wafers, up to
eight per patient, each with 7.7 mg of BCNU. Thus, a very
high concentration of BCNU is released in the brain,
which may be responsible for some of the adverse effects,
such as the seizures and brain edema seen in patients
implanted with BCNU wafers. Comparing these doses in
humans and extrapolating to mice, our in vivo dose of
0.5 mg/kg body weight in mice, an equivalent of 30 μM is
about 10-fold less compared to the dose in humans and,
so, not expected to cause any systemic or neuro-toxicity.
In fact we did not notice any signs of toxicity during the
entire treatment period. However, in mice significant toxi-
city of BCNU in terms of increased cell death has been
reported when BCNU is administered at 20 [49] or 10 [50]
mg/kg body weight. Because the LD50 dose in mice for
BCNU is 52 (males) and 46 (females) mg/kg body weight
[51], respectively, our dose of 0.5 mg/kg is about 100
times lower than the LD50 dose in mice or 20 to 40 times
lower than the doses used by other studies where signifi-
cant toxicity was encountered. Taken together our data
clearly suggest that BCNU reduces the levels of Ab40 as
determined using Ab-specific antibodies and amyloid pla-
que burden determined by thioflavin S staining at non-
toxic concentrations. Thus, this is definitive and confirma-
tory evidence that BCNU treatment reduces amyloido-
genic processing of APP in vivo.
The most interesting observation made in the present
study is that BCNU reduced amyloidogenic processing of
APP independent of secretases. Thus, the plethora of side
effects resulting from inhibition of secretases which is the
predominant reason for their failures in clinics can be
completely avoided [52,53]. The recent discovery of a cod-
ing mutation on the APP gene (A673T) which provides
significant protection against cognitive decline in both AD
patients as well as normal elderly individuals [54] is strong
proof of the principle evidence that reducing Ab levels is
an effective therapeutic approach for AD. Therefore, dis-
covery of any anti-Ab drug, especially those which modu-
late Ab generation independent of secretases would have
wider clinical applications. Our finding that BCNU has a
potent anti-Ab effect is in line with the anecdotal clinical
observations that AD and cancer are inversely related.
Although there is no epidemiological evidence linking
decreased risk of developing AD after chemotherapy, our
data suggest that cancer drugs, such as BCNU, can be
effective therapeutic agents against AD.
Conclusions
In summary, our data have revealed for the first time that
chronic BCNU administration at a non-toxic dose leads to
robust reduction of Ab40 levels and amyloid plaque bur-
den as a consequence of decreased amyloidogenic proces-
sing of APP. Decreased amyloid plaques may possibly
result from altered trafficking and processing of APP.
Thus, BCNU may emerge as a novel and powerful anti-Ab
drug for the effective treatment and prevention of AD.
Since BCNU acts independent of secretases, all the inad-
vertent side effects due to their off-target effects can be
completely avoided.
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